Global Small-scale Bioreactors Market

The global small-scale bioreactors market accounted for USD 1.94 billion in 2023 and is expected to reach at USD 8.91 billion by 2034 with a CAGR of 14.86% during the forecast period 2024-2034. The market will grow due to factors such as growing government funding, the need for cost-effective research and development, the need for biopharmaceuticals, the growing adoption of single-use technologies, and advancements in biotechnology research.

Personalized medicine is becoming more and more popular. It entails adjusting medical care to each patient's unique needs. Personalized treatments, including gene and cell therapies, are produced in small-scale bioreactors and necessitate careful control over growth conditions to preserve therapeutic efficacy and cell survival. For instance, in April 2023, Sartorius AG launched their BIOSTAT® SC single-use bioreactors in 50 and 200 L sizes, intending to streamline bioprocessing operations.

By product, the reusable bioreactors segment accounted for the highest revenue-grossing segment in the global small-scale bioreactors market in 2023 owing to the increasing emphasis on sustainability, durability, and long-term cost-effectiveness among biopharmaceutical manufacturers. For instance, Thermo Fisher Scientific Inc. introduced the Thermo Scientific NuncTM SimpliFloTM Single-Use Bioreactor System in December 2022; it is intended for scalable and effective cell cultivation. Additionally, the single-use bioreactors segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing adoption of flexible and scalable manufacturing solutions, reduced risk of cross-contamination, and lower upfront investment costs.

By capacity, the 1L-3L segment accounted for the highest revenue-grossing segment in the global small-scale bioreactors market in 2023 owing to the increased demand for small-scale bioprocessing in research and development, pilot-scale production, and personalized medicine applications. For instance, Merck KGaA announced in February 2024 that it will be developing and commercializing a novel single-use bioreactor platform for breakthrough medicines in partnership with a top biopharmaceutical business. Additionally, the 3L-5L segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising adoption of mid-scale bioprocessing for small-batch production, process optimization, and scale-up studies in biopharmaceutical manufacturing.

By end-user, the CROs & CMOs segment accounted for the highest revenue-grossing segment in the global small-scale bioreactors market in 2023 owing to the increasing outsourcing of biopharmaceutical manufacturing processes and research activities by pharmaceutical companies to streamline operations and reduce costs. For instance, Sartorius announced in January 2022 that it will acquire TAP Biosystems, a top supplier of cutting-edge cell culture technologies. The bioprocess solutions portfolio of Sartorius is strengthened by this acquisition. Additionally, the academic & research institutes segment is predicted to grow at the fastest CAGR during the forecast period owing to the expansion of biotechnology research programs, government funding initiatives, and growing collaborations with industry for drug discovery and bioprocess development.

North American region is anticipated to have the highest revenue share during the forecast period owing to the strong presence of biopharmaceutical companies, well-established research infrastructure, supportive regulatory environment, and high investment in biotechnology innovation. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly expanding biopharmaceutical market, increasing outsourcing of manufacturing activities, growing investment in biotechnology R&D, and favorable government policies promoting healthcare infrastructure development. For instance, in January 2022, the global developer and producer of state-of-the-art laboratory instruments for safety, process optimization, and scale-up, H.E.L Group, increased its activities in India with a greater focus on the rapid development of the biotech sectors. H.E.L. plans to set up a dedicated regional hub to provide clients with on-the-ground support for the nation's biotech and pharmaceutical industries.

This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.

Report Scope:

• Base Year: 2023
• Forecast Period: 2024-2034
• Study Coverage
• Market Forecast by Product, Capacity, and End-User
• Market Forecast for 5 Regions and 17+ Countries
• North America (U.S. and Canada)
• Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
• Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
• Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
• MEA (South Africa, GCC, Rest of MEA)
• Exhaustive Company Profiles of the Top 10+ Major Market Players

Segmentation: Small-scale Bioreactors Market Report 2023 - 2034

Small-scale Bioreactors Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)

• Reusable Bioreactors
• Stainless Steel Bioreactors
• Glass Bioreactor
• Single-use Bioreactors

Small-scale Bioreactors Market Analysis & Forecast by Capacity 2023 - 2034 (Revenue USD Bn)

• 5 ML -100 ML
• 100 ML-250 ML
• 250 ML -500 ML
• 500 ML-1 L
• 1L-3L
• 3L-5L

Small-scale Bioreactors Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)

• Pharmaceutical & Biopharmaceutical Companies
• CROs & CMOs
• Academic & Research Institutes

Small-scale Bioreactors Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)

• North America
• U.S.
• Canada
• Europe
• Germany
• France
• UK
• Spain
• Italy
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Rest of LATAM
• Middle East & Africa
• South Africa
• GCC
• Rest of MEA